2,6-Benzothiazolediamine, 4,5,6,7-Tetrahydro-N6-Propyl-, (S)-

Process-scale hydrogenation of (S)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole intermediates in multi-purpose GMP suites requires strict control of exothermic profiles when reducing the precursor imine or nitro functionalities that define this chiral synthon. Production batches executed in 500–2000 L Hastelloy C-22 reactors at 4–12 bar H₂ over 5% Pd/C (Johnson Matthey Type 487 or equivalent) exhibit a thermal runaway risk window between 55–68°C internal temperature, with differential scanning calorimetry onset at 72°C for the unprotected freebase. Quench-cooling loops sized for Δt ≥ 40°C across the jacket are mandatory under Process Safety Management protocols aligned to OSHA 29 CFR 1910.119. The (S)-N6-propyl diamine core serves as the primary pharmacophoric scaffold in non-ergoline dopamine D2/D3 agonist synthesis, with the free amine at C6 acylated or sulfonylated downstream to modulate receptor subtype selectivity. Final drug substance compliance testing references Ph.Eur. monograph 01/2024:2608 for related substances by HPLC-UV at 264 nm, with the benzothiazole chromophore providing sufficient molar absorptivity for 0.05% impurity LOQ without derivatization.

A Stereochemical Lock in D3-Preferring Agonist Design

Parkinsonian therapeutics requiring preferential D3 over D2 receptor occupancy exploit the (S)-absolute configuration at C6 to restrict rotational freedom of the propylamino sidechain within the orthosteric binding pocket defined by transmembrane helices 3, 5, and 6. The enantiomeric excess specification for advanced intermediates entering the final amidation step is ≥ 99.0% ee by chiral HPLC (Chiralpak AGP, 150 × 4.6 mm, phosphate buffer pH 6.2/acetonitrile 92:8, 0.5 mL/min, retention of (R)-enantiomer relative to (S) = 1.38). Manufacturing deviations below 98.5% ee cascade into D2-mediated dyskinesia liabilities detectable only at Phase II clinical endpoints, making chiral integrity a critical quality attribute (CQA per ICH Q6A, Section 2.3).

Addition ratio: The diamine is consumed at 1.00–1.05 molar equivalents relative to the activated carboxylic acid coupling partner (typically a 2-aminothiazole-4-acetic acid derivative pre-activated with HOBt/EDC in DMF at 0–5°C). Excess freebase beyond 1.10 equivalents depresses amidation yield via competitive N-acylation at the sterically less hindered C2-amine, generating a regioisomeric impurity that co-elutes with the product on conventional C18 stationary phases. Production process: The isolated (S)-diamine freebase is charged to a Schott DURAN reactor under nitrogen overlay, dissolved in anhydrous N,N-dimethylacetamide (KF < 200 ppm) at 8–10 volumes, and treated with a pre-formed mixed anhydride stream over 90–120 minutes with jacket temperature maintained at −5 ± 3°C. Post-quench phase split with 2-methyltetrahydrofuran removes polar additives; the organic layer is washed with 5% aqueous sodium bicarbonate until conductivity of the aqueous phase drops below 200 µS/cm. Terminal product class: N-acylated (S)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine derivatives represent the penultimate intermediate before salt formation and final recrystallization to yield dopamine agonist hydrochloride monohydrate drug substances, filed under US DMF Type II with closed-portion stereochemical justification referencing single-crystal X-ray structures determined with Mo Kα radiation at 100 K.

Diastereomeric Salt Resolution Scale-Up: Solubility Phase Diagrams and Ternary Equilibria

Racemic tetrahydrobenzothiazole diamine produced via reductive amination of 2,6-diamino-4,5,6,7-tetrahydrobenzothiazole with propionaldehyde and sodium triacetoxyborohydride (NaBH(OAc)₃) in 1,2-dichloroethane at 20–25°C is resolved through fractional crystallization of diastereomeric salts with (2R,3R)-O,O’-dibenzoyltartaric acid (D-DBTA) in ethanol:water mixtures. The ternary phase diagram for the (S)-diamine/(R)-diamine/D-DBTA system at 25°C in ethanol:water (85:15 v/v) exhibits a eutectic composition at 62 mol% (R)-enantiomer, with pure (S)-diamine·D-DBTA salt precipitating at enantiomeric excess exceeding 87% in the mother liquor. Published data for this specific system at production concentrations above 0.45 M is limited to in-house process development reports; however, polymorphism screening by parallel crystallization in 96-well microtiter plates (Technobis CrystalBreeder, 250 µL scale, 0.3°C/min cooling rate) identified two anhydrous forms and one ethanol hemisolvate with distinct DSC endotherms at 148.2°C, 162.7°C, and 131.5°C, respectively. The hemisolvate form is kinetically favored below 40°C but converts to the thermodynamically stable anhydrous Form I upon slurry ripening at 50°C for 16 hours.

Regulatory compliance for chiral resolution auxiliaries: D-DBTA residual in the isolated freebase must meet the limit of ≤ 0.15% w/w per USP general chapter <232> elemental impurity limits for dibenzoyl derivatives when the target drug substance is destined for chronic-use indications (> 10 years expected exposure). Addition ratio: D-DBTA is charged at 1.00–1.02 molar equivalents per mole of total diamine enantiomers, with a slight excess to suppress oiling-out phenomena observed when the unresolved freebase concentration exceeds 0.52 M. Production equipment for the resolution step employs a Pfaudler glass-lined baffled crystallizer (model AE-1000, retreat-curve impeller, 45 rpm tip speed) with a programmable PT-100 temperature cascade controlling both jacket inlet and external circulation loop heaters. Final product classification: the D-DBTA salt is decomposed with 10% w/w aqueous NaOH to release the (S)-enantiomer as freebase, which is extracted into 2-MeTHF and isolated as the dihydrochloride salt by treatment with ethanolic HCl at −10°C for transport as a stable, non-hygroscopic crystalline solid with confirmed stoichiometry by argentometric titration (potentiometric endpoint, combined Ag/AgCl electrode, Metrohm Titrando).

Non-Ergot Dopamine Agonist Active Pharmaceutical Ingredient

When the free amine at the C6 position of the (S)-tetrahydrobenzothiazole scaffold is propionylated with propionic anhydride in the presence of triethylamine in dichloromethane at reflux (39–40°C), the resulting N6-propionyl-N6-propyl derivative achieves the final structural architecture of the dopamine agonist API. This divergent point in the synthetic route is pH-sensitive due to competing lactamization between the C2-amine and the adjacent thiazole nitrogen under acidic aqueous workup (pH < 4.0). Batch records from commercial manufacturing lines document an isolated yield loss of 11–14% when post-reaction quench pH drifts below 4.5 prior to phase separation. Production equipment specification: Büchi midiPilot glass reactor with Hastelloy C-276 internals, 30 L working volume, equipped with a condenser operating at −15°C glycol supply to minimize dichloromethane evaporative losses during exothermic propionic anhydride addition. Compliance: ICH Q3C(R8) Option 2 limits for dichloromethane (600 ppm) and triethylamine (320 ppm) are verified by headspace GC-FID on each isolated batch before release to the formulation step. The terminal API is manufactured as the monohydrochloride monohydrate under EU GMP Part II Annex 15 qualification protocols; tablet formulation follows wet granulation with lactose monohydrate and pregelatinized starch, compressed at 8–12 kN on a Fette 2090 rotary press to target hardness of 70–100 N (Ph.Eur. 2.9.8).

Residual palladium from the upstream hydrogenation is controlled to ≤ 10 ppm (USP <232>, Class 1 Element) using a SiliaMetS Thiol metal scavenger cartridge (loading: 1.2 mmol/g, residence time ≥ 8 minutes) in-line after carbon filtration through a Zeta Plus 60SP depth filter. The thiol-functionalized silica scavenger also reduces residual ruthenium from alternative catalyst systems (Ru/C at 2% loading, tested during supply chain interruptions) to levels below 5 ppm, though ruthenium-catalyzed substrate exhibited 3–4% higher dechlorinated impurity compared to standard 5% Pd/C process when evaluated by LC-MS total ion chromatogram peak area normalization at 254 nm.

Polybenzothiazole Precursor via Thermal Cyclodehydration

Thermally activated polycondensation of tetrafunctional benzothiazole-diamine monomers with aromatic dianhydrides (most critically 3,3′,4,4′-biphenyltetracarboxylic dianhydride, BPDA) yields poly(benzothiazole-imide) copolymers with coefficients of thermal expansion below 8 ppm/°C in the glassy state, measured by thermomechanical analysis (TMA) per ASTM E831-19 at 10°C/min heating rate under nitrogen. The ortho-diamine arrangement within the tetrahydrobenzothiazole ring system enables polybenzothiazole formation through a two-stage imidization-cyclodehydration sequence: initial poly(amic acid) formation in NMP at 0–5°C (exothermic neutralization of the free amine groups with polyamic acid carboxylic acids requires controlled monomer addition over 4 hours), followed by thermal cyclodehydration at 280–320°C under vacuum for 6–8 hours. Residual solvent in the pre-imidized film causes blister defects when the cyclodehydration ramp rate between 150–220°C exceeds 3°C/min; DMA (TA Instruments Q800, 1 Hz, 3°C/min ramp) confirms that the glass transition temperature of the fully cyclized copolymer shifts from 287°C to 298°C when the BPDA:(S)-diamine stoichiometric imbalance is narrowed from 1.02:1.00 to 1.004:1.000.

Standard test methods: IPC-TM-650 method 2.4.24.5 governs the time-delamination test at 288°C solder float simulation; finished flexible copper-clad laminates incorporating this polybenzothiazole-imide as the dielectric layer must withstand 10 seconds minimum delamination time. The (S)-propyl sidechain contributes to chain-packing disruption that reduces in-plane orientation relative to fully aromatic benzothiazole-imide backbones, producing a slight loss of tensile modulus (from ~8.3 GPa for the unsubstituted analogue to ~7.1 GPa for the N6-propyl variant, tested per ASTM D882-18 at 50 mm/min) but a measurable gain in elongation at break from 12% to 21%. Addition ratio in varnish formulation: 47.0–49.5 wt% total solids in NMP, with the diamine comonomer comprising 24.0–25.5% of that solid fraction, the remainder being BPDA and phthalic anhydride endcapper. Terminal product class: flexible printed circuit (FPC) basefilms for applications requiring continuous dynamic flexing at operating temperatures exceeding 200°C, supplied in 25 µm and 50 µm gauge thicknesses with a targeted dielectric constant of 3.2 ± 0.1 at 1 GHz per IPC-4101E Specification 4.2.2. Equipment: the poly(amic acid) casting solution is slot-die coated on a Hirano Tecseed precision coater with 0.3 m/min line speed onto a polished stainless-steel belt in a Class 1000 cleanroom maintained at 22 ± 1°C and RH < 35%.

Cross-Coupling Substrate for Buchwald-Hartwig Amination

Steric accessibility of the C2 aromatic amine in the benzothiazole ring permits chemoselective palladium-catalyzed N-arylation while leaving the secondary N6-propyl amine untouched, provided the electron-rich biarylphosphine ligand generates a sufficiently electrophilic Pd(II) center. A process optimization study performed on 500 g scale in a HEL AutoMATE parallel reactor identified Xantphos (4 mol%, Pd₂(dba)₃ precatalyst at 2 mol%) in toluene at 100°C with sodium tert-butoxide base (1.4 equivalents) as the condition set that achieves 91% isolated yield of C2-N-arylated product with < 0.5% N6-arylated regioisomer detected by qNMR (internal standard: 1,3,5-trimethoxybenzene, δ 6.12 ppm in DMSO‑d₆). The freebase form of the diamine is essential; attempted direct coupling of the dihydrochloride salt yielded 38% conversion after 24 hours due to slow in-situ neutralization kinetics in the non-polar reaction medium. Equipment: the exotherm associated with sodium tert-butoxide addition to wet toluene (water content ≥ 300 ppm) triggered a 14 K adiabatic temperature rise in the HEL Phi-TEC II adiabatic calorimeter at phi-factor 1.05, mandating a controlled reagent addition rate slower than 0.15 mol/L reactor volume/hour and a reactor jacket with > 50 W/kg cooling capacity.

Compliance: the resulting C2-N-aryl intermediates enter drug discovery programs evaluated under ICH M7(R2) for mutagenic impurities; the absence of the N6-arylated regioisomer eliminates an Ames-positive structural alert (aromatic amine without ortho-substitution) during structure-activity relationship analysis per the(QSAR models of DEREK Nexus v 6.3.0. The product class comprises extended benzothiazole-diamine libraries destined for high-throughput D2/D3 binding affinity screening using [³H]-spiperone displacement in CHO cell membranes expressing human recombinant receptors (IC₅₀ determination per CEREP ExpresSProfile at 8 concentrations in duplicate). Stoichiometric ratio for the C2-selective arylation step is 1.00:1.05 diamine:aryl bromide; excess aryl bromide above 1.10 equivalents results in doubly arylated material as a crystalline impurity with melting point 178–180°C that co-precipitates during the product’s anti-solvent crystallization from heptane/toluene (3:1 v/v).

Imine-Linked Covalent Organic Framework Node

Combining the ditopic (S)-propyl-tetrahydrobenzothiazole-diamine with tris(4-formylphenyl)amine under solvothermal conditions in mesitylene/dioxane (4:1 v/v) with 6 M aqueous acetic acid catalyst (0.2 mL per 10 mL total volume) at 120°C for 72 hours in a flame-sealed Pyrex ampoule generates a chiral imine-linked COF with BET surface area measured at 1,190 m²/g (Micromeritics ASAP 2460, N₂ at 77 K, degas at 120°C for 12 hours under dynamic vacuum). The (S)-propyl sidechain projects into the one-dimensional hexagonal pore channels of the eclipsed AA-stacked framework, imparting pore-wall chirality that differentiates this structure from analogous COFs synthesized with racemic or unsubstituted diamine monomers. Powder X-ray diffraction (Cu Kα, 40 kV, 30 mA, step size 0.02° 2θ) of the activated material displays the 100 reflection at 2θ = 2.6°, corresponding to a d-spacing of approximately 34 Å and a pore diameter of approximately 29 Å by NLDFT cylindrical pore model. Compliance alignment: no specific GMP or ISO standard governs COF production at research scale, but batch-to-batch reproducibility of the BET surface area within ± 8% is confirmed over 11 consecutive syntheses when the diamine monomer enantiomeric purity exceeded 99.0% ee.

Addition ratio: the nominal diamine:trialdehyde stoichiometry is 3:2 (amine:aldehyde molar basis), with trialdehyde charged at 2.5 mol% excess to correct for its lower solubility in the mesitylene-rich solvent system at ambient temperature prior to ampoule sealing. Terminal product class: the imine-linked chiral COF serves as a stationary phase candidate for enantioselective chromatographic separation of racemic secondary alcohols (hexahelicene test probe, α = 1.12) when packed into a 250 × 4.6 mm stainless-steel HPLC column at 7000 psi backpressure using a pneumatic packing pump. Equipment constraints: the solvothermal ampoule method limits single-batch yield to approximately 1.2 g of activated COF per 20 mL ampoule, and attempts to scale in a Parr 4848 stirred pressure reactor at 125°C exhibited 60% lower crystallinity by PXRD peak height ratio (100 to amorphous halo), attributed to insufficient static growth conditions under agitation. Published data for continuous-flow COF synthesis protocols using this specific chiral diamine is limited to preliminary microfluidic feasibility reports at < 1 mL/min flow rates.